A phase I pharmacokinetic evaluation of oral arsenic trioxide in previously untreated patients with acute promyelocytic leukaemia

DOI number 10.58109/7qkt-m731
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Harry Iland (Royal Prince Alfred Hospital)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 31 Patients with newly diagnosed APL
  • Randomised controlled trial, with patients receiving oral arsenic, vs intravenous arsenic
  • Dataset includes diagnostic data, treatment data, outcome data
  • Cancer Australia demographic data
    -Year of birth
    -Aboriginal or Torres Strait Islander status (or Ethnicity)
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Chemotherapy
ANZCTR Reference ACTRN12616001022459
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
APML04
BM07